ALKS news

Alkermes plc reported third-quarter 2026 revenue of $480.1 million, with GAAP net income of $16.3 million, reiterating full-year financial expectations.

Alkermes announced a Phase 1b study of ALKS 7290 demonstrated clinically meaningful, dose-dependent improvements in ADHD symptoms in adult patients, highlighting potential for differentiated therapies in a high-need area.

Alkermes plc announced the appointment of seasoned biopharmaceutical executive Anne C. Whitaker to its Board of Directors at a time of strategic growth and developing pipeline opportunities.

Alkermes reported Q2 2026 revenues of $496.0 million and adjusted EBITDA of $139.2 million. The company also announced Blair Jackson will become CEO effective August 1, succeeding Richard Pops.

Alkermes announced that its investigational narcolepsy and idiopathic hypersomnia treatment alixorexton received orphan drug designations from the FDA and European Commission, providing development incentives and market exclusivity if approved. The designations support the company's ongoing phase 3 …

Alkermes plc filed an amended 2018 Stock Option and Incentive Plan governing equity awards for officers, employees, directors and consultants. The plan amendment is relevant to investors as it affects executive compensation structure and employee incentive alignment.